By exposing them to tumor antigens, dendritic cell (DC) therapy seeks to stimulate T-cell proliferation and encourage the activation of CD4+ and CD8+ T-cells, enabling CD8+ T-cells to penetrate the tumor microenvironment. The gene discussed is CD8A; the disease is neoplasm.